Refractory VT/VF, Prospective Evaluation to Differentiate Lidocaine Efficacy from Nifekalant

Refractory VT/VF, Prospective Evaluation to Differentiate Lidocaine Efficacy from Nifekalant - RELIEF Study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000001781

Enrollment

Registered

2009-03-18

Start date

2005-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ventricular tachycardia, Ventricular fibrillation

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: In-hospital sustained VT/VF resistant to at least 2 shocks

Exclusion criteria

Exclusion criteria: Drug-induced long QT syndrome Congenital long QT syndrome

Design outcomes

Primary

Measure	Time frame
Termination of VT/VF with/without shock	—

Secondary

Measure	Time frame
Return of spontaneous circulation, One-month survival, Discharge alive from the hospital, Adverse events: asystole,pulseless electrical activity, Torsades de pointes, QT prolongation(>0.55)	—

Countries

Japan

Contacts

Public ContactTsuyoshi Shiga

Tokyo Women's Medical University Cardiology

mshiga@hij.twmu.ac.jp03-3353-8111

Outcome results